Acadia Pharmaceuticals
ACAD
296 hedge funds and large institutions have $2.99B invested in Acadia Pharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 71 funds opening new positions, 108 increasing their positions, 74 reducing their positions, and 29 closing their positions.
145% more first-time investments, than exits
New positions opened: 71 | Existing positions closed: 29
137% more call options, than puts
Call options by funds: $18.4M | Put options by funds: $7.74M
67% more funds holding in top 10
Funds holding in top 10: 3 → 5 (+2)
46% more repeat investments, than reductions
Existing positions increased: 108 | Existing positions reduced: 74
24% more capital invested
Capital invested by funds: $2.4B → $2.99B (+$583M)
16% more funds holding
Funds holding: 256 → 296 (+40)
3.66% more ownership
Funds ownership: 94.22% → 97.88% (+3.7%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$90.7M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$36M |
| 3 |
SG Americas Securities
New York
|
+$31.7M |
| 4 |
Citigroup
New York
|
+$25M |
| 5 |
Goldman Sachs
New York
|
+$18.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
-$80.7M |
| 2 |
State Street
Boston,
Massachusetts
|
-$23.4M |
| 3 |
Millennium Management
New York
|
-$15.1M |
| 4 |
FC
Finepoint Capital
Boston,
Massachusetts
|
-$13.9M |
| 5 |
O
OrbiMed
New York
|
-$11.8M |
ACAD Hedge Fund Activity: Q4 2024 in Review
296 of the 7,606 institutional investors tracked by Wall St. Rank reported a position in Acadia Pharmaceuticals (ACAD) for Q4 2024, worth a combined $2.99B — up 24% from $2.4B a quarter earlier.
Buyers outnumbered sellers: 71 funds opened new ACAD positions and 29 closed out — a net gain of 42 holders — while 108 added to existing stakes and 74 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $90.7M. The largest seller was RTW Investments, cutting an estimated $80.7M.
- 296 institutional investors held Acadia Pharmaceuticals (ACAD) as of Q4 2024, up from 256 in Q3 2024.
- Funds reported $2.99B of Acadia Pharmaceuticals stock for Q4 2024, up 24% quarter-over-quarter.
- 71 funds opened new Acadia Pharmaceuticals positions in Q4 2024 and 29 closed out, a net change of +42 holders.
- The largest Acadia Pharmaceuticals buyer in Q4 2024 was Morgan Stanley, an estimated $90.7M added.
- The largest Acadia Pharmaceuticals seller in Q4 2024 was RTW Investments, an estimated $80.7M sold.
Based on aggregated 13F filings for Q4 2024.